Endocrine Essentials for Primary Care - Atlanta
Endocrine Essentials for Primary Care - Atlanta
The Endocrine Society brings top-quality clinical updates to your area with Endocrine Essentials Live. This regional series features two programs designed for both professional endocrinologists and for primary care physicians treating endocrine-related diseases.
To claim CME
- This form is for the Endocrine Essentials for Primary Care meeting in Atlanta, GA on September 20, 2014
- To evaluate this meeting and claim CME, click "Take Course" to the right
This continuing medical education activity should be of substantial interest to primary care physicians, nurse practitioners, registered nurses, certified diabetes educators and other healthcare professionals who treat patients with diabetes, bone or thyroid disorders.
Upon completion of this educational activity, learners will be able to:
- Identify the clinical and behavioral barriers to achieving weight loss and preventing weight gain in overweight and obese patients
- Explain the clinical benefits of losing 5% to 10% of excess body weight
- Explore how newly-approved and emerging weight- loss drugs may be appropriately integrated into a weight-loss program
- Discuss the clinical data on new pharmaceutical treatment options for obesity
- Recognize the behavioral approaches to obesity management that are most impactful in practice
- Define medically significant weight loss and its impact on glycemic parameters
- Select appropriate medical therapy options for the co-management of diabetes and obesity
- Explain the role new agents have in assisting current therapeutic challenges
- Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience
- Compare and critique current glycemia algorithms and discuss the place for new therapies within them
- Recognize the progression of beta-cell dysfunction in the pathophysiology of T2DM
- Employ appropriate techniques to achieve and maintain normoglycemia in in-patients
- Recognize when a patient would benefit from starting basal insulin
- Explain the fundamentals of team-based care and how to implement when starting and titrating basal insulin
- Assess the benefits to starting insulin in a patient with poorly controlled diabetes
- Explain to patients the need for mealtime insulin
- Summarize the discussions of the validity of low testosterone
- Perform appropriate evaluation of symptomatic men to determine if they are androgen deficient
- Explain the rationale behind key accountability and quality improvement measures in the diagnosis and management of men with androgen deficiency
Shehzad Basaria, MD – Boston Medical Center
George Bray, MD – Pennington Biomedical Research Institute
Marc-Andre Cornier, MD – University of Colorado
Mark Molitch, MD – Northwestern University, Feinberg School of Medicine
Francisco Pasquel, MD – Emory University School of Medicine
Priyathama Vellanki, MD – Emory University School of Medicine
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
Shehzad Basaria, MD: Consultant, Eli Lilly & Co., Endo Pharma; Investigator, AbbVie Pharmaceuticals
George Bray, MD, MACP, MACE: Advisor, Medifast, Inc.; Speaker, Herbalife International of America, Inc., Vivus, Inc.
Mark Molitch, MD: Consultant, Chiasma/Genentech, Lilly; Consultant and Research Grant Support, Corcept, Ipsen, Novartis, Novo Nordisk
The following faculty reported no relevant financial relationships: Marc-Andre Cornier, MD; Francisco Pasquel, MD; Priyathama Vellanki, MD
The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
- 5.00 AMA PRA Category 1 Credits™
- 5.00 CME Certificate of Participation